Assembly Bio Expands ABI-6250 Into Liver Diseases
SOUTH SAN FRANCISCO, Calif., May 22, 2026 Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SOUTH SAN FRANCISCO, Calif., May 22, 2026 Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its...
FOSTER CITY, Calif., May 4, 2026 Mirum Pharmaceuticals, Inc. has announced that its Phase 2b VISTAS clinical study of...
